By Counterforce Health Team in Gilenya (fingolimod) —

How to Get Gilenya (Fingolimod) Covered by Aetna CVS Health in Washington: 2025 Prior Authorization Guide

Answer Box: Quick Path to Coverage

Aetna CVS Health requires prior authorization for Gilenya (fingolimod) in Washington, with mandatory step therapy through generic fingolimod first. Your neurologist must document relapsing MS diagnosis, submit baseline EKG and monitoring plan, and provide evidence of generic failure/intolerance for brand approval. If denied, you have 180 days to appeal internally, then 123 days for Washington's external review. Start today: Contact your neurologist to gather medical records and initiate the prior authorization through CVS Specialty Pharmacy at 1-800-237-2767.

Table of Contents

  1. Aetna's Policy Overview
  2. Medical Necessity Requirements
  3. Step Therapy & Brand Exceptions
  4. Required Diagnostics & Monitoring
  5. CVS Specialty Pharmacy Requirements
  6. Common Denial Reasons & Solutions
  7. Washington Appeals Process
  8. Cost-Saving Options
  9. FAQ

Aetna's Policy Overview

Aetna CVS Health treats Gilenya (fingolimod) as a specialty medication requiring prior authorization and step therapy across all plan types—commercial, Medicare, and Medicaid. The policy applies to both brand Gilenya and generic fingolimod, though with different requirements.

Coverage at a Glance

Requirement Details Documentation Needed
Prior Authorization Required for all strengths Completed PA form from neurologist
Step Therapy Generic fingolimod first Proof of generic trial/failure
Age Restriction ≥10 years old Date of birth verification
Prescriber Neurologist or consultation Specialist credentials
Monitoring Plan EKG, ophthalmology, labs Baseline test results
Quantity Limit One capsule daily Standard dosing justification

The policy is updated annually, so always verify current requirements through your Aetna member portal or CVS Specialty Pharmacy.

Medical Necessity Requirements

Aetna only covers Gilenya for FDA-approved indications: relapsing forms of multiple sclerosis in patients 10 years and older. This includes relapsing-remitting MS, clinically isolated syndrome, and active secondary progressive MS with relapses.

Required Clinical Documentation:

  • Confirmed diagnosis of relapsing MS with ICD-10 code
  • Documentation of relapse history or MRI evidence of activity
  • Treatment goals and expected outcomes
  • Weight-based dosing justification (0.25mg for ≤40kg, 0.5mg for >40kg)
Clinician Corner: Your medical necessity letter should reference the FDA prescribing information and include specific language about "relapsing forms of MS" rather than just "multiple sclerosis" to align with Aetna's policy language.

Step Therapy & Brand Exceptions

Aetna requires patients to try generic fingolimod first before approving brand Gilenya. This step therapy requirement is the most common reason for initial denials.

Step-by-Step: Getting Brand Gilenya Approved

  1. Document Generic Trial - Your neurologist must prescribe generic fingolimod and document the outcome
  2. Prove Inadequate Response - Show lack of efficacy after appropriate trial period (typically 3-6 months)
  3. Document Intolerance - Record specific adverse effects that prevent generic use
  4. Submit Exception Request - Include detailed clinical notes and rationale
  5. Provide Contraindication Evidence - If applicable, document medical reasons generic cannot be used

Medical Exception Pathways:

  • Documented allergic reaction to generic formulation
  • Significant adverse effects not seen with brand
  • Bioequivalence concerns with specific clinical evidence
  • Swallowing difficulties requiring Tascenso ODT formulation

Required Diagnostics & Monitoring

Gilenya's first-dose monitoring requirements are often overlooked in prior authorization submissions, leading to denials.

Pre-Authorization Checklist:

  • Baseline EKG (within 6 months)
  • Complete blood count with lymphocyte count
  • Liver function tests
  • Ophthalmologic examination for macular edema screening
  • Vaccination status (live vaccines contraindicated)
  • First-dose monitoring plan with 6-hour observation protocol

Monitoring Documentation Requirements:

  • Facility capable of EKG monitoring and emergency response
  • Plan for hourly vital signs during 6-hour observation
  • Post-dose EKG at 6 hours
  • Extended monitoring criteria if heart rate <45 bpm or new conduction abnormalities
Tip: Many denials occur because the monitoring plan is incomplete. Include the specific facility where first-dose monitoring will occur and confirm they have appropriate emergency equipment.

CVS Specialty Pharmacy Requirements

All Gilenya prescriptions must be filled through CVS Specialty Pharmacy after the initial "grace fill" at a retail pharmacy. This requirement is non-negotiable for Aetna members.

Specialty Pharmacy Process:

  1. Initial Fill - May be obtained at any network pharmacy
  2. Transfer to CVS Specialty - Required for all refills
  3. Specialty Guideline Management - Ongoing clinical review
  4. Home Delivery - Standard 30-90 day supplies available

Contact CVS Specialty at 1-800-237-2767 to initiate enrollment and confirm current coverage status.

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
Step therapy not met Document generic trial/failure Clinical notes, prescription history
Missing monitoring plan Submit complete safety protocol EKG facility info, observation plan
Non-formulary status Request formulary exception Medical necessity letter, guidelines
Quantity limit exceeded Justify dosing frequency Weight-based dosing rationale
Missing baseline tests Complete required screening Lab results, EKG, eye exam
Prescriber not specialist Get neurologist consultation Referral documentation

From Our Advocates: We've seen many Gilenya denials overturned by including the specific FDA safety language about first-dose monitoring in the appeal. Payers often approve when they see the prescriber understands and can implement the required safety protocols.

Washington Appeals Process

Washington state provides strong consumer protections for insurance denials, including specialty drug coverage decisions.

Internal Appeals Timeline:

  • Level 1: File within 180 days of denial
  • Level 2: File within 60 days of Level 1 denial
  • Contact: Mail to PO Box 14463, Lexington, KY 40512 or fax 1-859-425-3379

External Review (IRO): After exhausting internal appeals, you can request an Independent Review Organization review within 123 days of your final denial. The IRO decision is binding on Aetna.

Washington-Specific Resources:

Expedited Appeals: Available when delay could seriously jeopardize your health. Standard timeline reduces to 72 hours for urgent cases.

Cost-Saving Options

Even with insurance coverage, Gilenya can involve significant out-of-pocket costs.

Financial Assistance Programs:

  • Novartis Patient Assistance: Income-based free medication program
  • Gilenya Co-pay Support: Up to $100/month copay reduction for eligible patients
  • Washington State Prescription Drug Program: Additional state-level assistance
  • Foundation Grants: Multiple sclerosis-specific organizations offer medication grants

Generic fingolimod offers substantial savings—cash prices often under $1,000/month compared to brand Gilenya's $10,000+ monthly cost.

FAQ

How long does Aetna prior authorization take for Gilenya? Standard decisions typically take 30-45 days. Expedited reviews for urgent cases are completed within 72 hours.

What if Gilenya isn't on my formulary? You can request a formulary exception by demonstrating medical necessity and providing clinical evidence supporting Gilenya over formulary alternatives.

Can I appeal if I live in Washington but have an employer plan? Self-funded ERISA plans may not be subject to Washington state appeal rights, but many voluntarily provide similar processes. Contact your HR department for plan-specific procedures.

Does step therapy apply if I've tried other MS medications outside Washington? Yes, prior therapy documentation from any state is generally accepted. Provide complete medical records showing previous treatments and outcomes.

What's the difference between brand Gilenya and generic fingolimod for coverage? Both require prior authorization, but brand Gilenya requires additional step therapy documentation showing generic failure or intolerance.

How do I get expedited approval for Gilenya? Your neurologist must document that delay in treatment would seriously jeopardize your health. Include clinical evidence of disease progression or relapse activity.

When navigating insurance coverage becomes overwhelming, Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters, identifies specific policy requirements, and generates point-by-point rebuttals using the right medical evidence and payer-specific workflows. For complex cases like Gilenya coverage, having expert support can make the difference between approval and continued delays.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for the most current coverage requirements and medical recommendations. Coverage policies and appeal procedures may change; verify current information through official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.